Vittoria Nanna

Vittoria Nanna

Auto-generated profile, based on publicly available information

Vittoria Nanna

CNR − Institute of Crystallography, Via Amendola 122/o, Bari 70126, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
MLMaria Cristina Lomuscio
Maria Cristina Lomuscio
NCNicola Corriero
Nicola Corriero
VNVittoria Nanna
Vittoria Nanna
APAntonio Piccinno
Antonio Piccinno
MSMichele Saviano
Michele Saviano
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi
Developing sigma-1 receptor (S1R) modulators is considered a valuable therapeutic strategy to counteract neurodegeneration, cancer progression, and viral infections, including COVID-19.

16 April 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
DADomenico Alberga
Domenico Alberga
VNVittoria Nanna
Vittoria Nanna
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
AAAdolfo Ancona
Adolfo Ancona
MLMaria Cristina Lomuscio
Maria Cristina Lomuscio
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi
Achieving optimal target activity while maintaining synthetic accessibility and drug-likeness represents a major challenge in computational drug discovery. Existing de novo generative models often yield chemically invalid or synthetically intractable structures and struggle to optimize multiple objectives simultaneously. Here, we introduce ALCHIMIA, an interpretable hybrid framework combining reinforcement learning (RL) and a genetic algorithm (GA), built based on a vocabulary of 33 medicinal chemistry-inspired molecular transformations. The RL component trains a policy network to prioritize transformation sequences that improve synthetic accessibility (SA) and the quantitative estimate of drug-likeness (QED) scores, embedding these constraints directly into molecular generation. The GA component applies the learned policy as a mutational operator within population-based optimization guided by molecular docking, enabling the exploration of diverse chemical lineages while converging toward high-affinity ligands. ALCHIMIA was applied to two different pharmacologically relevant targets: human Cannabinoid Receptor 2 (CB2R) and human Sigma nonopioid intracellular Receptor 1 (S1R). We considered three different scenarios: (i) unconstrained hit identification; (ii) scaffold-constrained lead optimization; and (iii) design of dual modulators. The framework generated chemically valid molecules with QED and SA scores comparable to or better than those obtained with random baselines and selected de novo design methods. By codifying typical medicinal chemistry actions as learnable transformations and coupling multiobjective optimization with GA-based diversity maintenance, ALCHIMIA, freely available as a GitHub repository (https://github.com/alberdom88/ALCHIMIA), provides a practical, interpretable, and scalable framework for molecular de novo design.

18 June 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NSNaira Samarina
Naira Samarina
GSGeorge Ssebyatika
George Ssebyatika
TTTanvi Tikla
Tanvi Tikla
JWJa-Yun Waldmann
Ja-Yun Waldmann
BABizunesh Abere
Bizunesh Abere
TSThomas Schultz
Thomas Schultz
Kaposi Sarcoma-associated herpesvirus (KSHV) causes three human malignancies, Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL) and the plasma cell variant of multicentric Castleman’s Disease (MCD), as well as an inflammatory cytokine syndrome (KICS). Its non-structural membrane protein, pK15, is among a limited set of viral proteins expressed in KSHV-infected KS tumor cells. Following its phosphorylation by Src family tyrosine kinases, pK15 recruits phospholipase C gamma 1 (PLCγ1) to activate downstream signaling cascades such as the MEK/ERK, NFkB and PI3K pathway, and thereby contributes to the increased proliferation and migration as well as the spindle cell morphology of KSHV-infected endothelial cells. Here, we show that a phosphorylated Y481EEVL motif in pK15 preferentially binds into the PLCγ1 C-terminal SH2 domain (cSH2), which is involved in conformational changes occurring during the activation of PLCγ1 by receptor tyrosine kinases. We determined the crystal structure of a pK15 12mer peptide containing the phosphorylated pK15 Y481EEVL motif in complex with a shortened PLCγ1 tandem SH2 (tSH2) domain. This structure demonstrates that the pK15 peptide binds to the PLCγ1 cSH2 domain in a position that is normally occupied by the linker region connecting the PLCγ1 cSH2 and SH3 domains. We also show that longer pK15 peptides containing the phosphorylated pK15 Y481EEVL motif can increase the Src-mediated phosphorylation of the PLCγ1 tSH2 region in vitro. This pK15-induced increase in Src-mediated phosphorylation of PLCγ1 can be inhibited with the small pK15-derived peptide which occupies the PLCγ1 cSH2 domain. Our findings thus suggest that pK15 may act as a scaffold protein to promote PLCγ1 activation in a manner similar to the cellular scaffold protein SLP-76, which has been shown to promote PLCγ1 activation in the context of T-cell receptor signaling. Reminiscent of its positional homologue in Epstein-Barr Virus, LMP2A, pK15 may therefore mimic aspects of antigen-receptor signaling. Our findings also suggest that it may be possible to inhibit the recruitment and activation of PLCγ1 pharmacologically.

17 February 2024 in ACS Infectious Diseases
Verified
Journal Article
Open access
SJSandra Johannsen
Sandra Johannsen
RGRobin M. Gierse
Robin M. Gierse
AKArne Krüger
Arne Krüger
RERachel L. Edwards
Rachel L. Edwards
VNVittoria Nanna
Vittoria Nanna
AHAnna Hirsch
Anna Hirsch
In this study, we identified three novel compound classes with potent activity against Plasmodium falciparum, the most dangerous human malarial parasite. Resistance of this pathogen to known drugs is increasing, and compounds with different modes of action are urgently needed. One promising drug target is the enzyme 1-deoxy-d-xylulose-5-phosphate synthase (DXPS) of the methylerythritol 4-phosphate (MEP) pathway for which we have previously identified three active compound classes against Mycobacterium tuberculosis. The close structural similarities of the active sites of the DXPS enzymes of P. falciparum and M. tuberculosis prompted investigation of their antiparasitic action, all classes display good cell-based activity. Through structure-activity relationship studies, we increased their antimalarial potency and two classes also show good metabolic stability and low toxicity against human liver cells. The most active compound 1 inhibits the growth of blood-stage P. falciparum with an IC50 of 600 nM. The results from three different methods for target validation of compound 1 suggest no engagement of DXPS. All inhibitor classes are active against chloroquine-resistant strains, confirming a new mode of action that has to be further investigated.

5 February 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FMFrancesco Mastropasqua
Francesco Mastropasqua
ALAnna Teresa Lisi
Anna Teresa Lisi
LCLucie Crouzier
Lucie Crouzier
GMGabriella Rosanna Musillo
Gabriella Rosanna Musillo
FAFrancesca Serena Abatematteo
Francesca Serena Abatematteo
CACarmen Abate
Carmen Abate

1 August 2025 in ACS Omega
Verified
Journal Article
Open access
GMGiovanni Mattiotti
Giovanni Mattiotti
VNVittoria Nanna
Vittoria Nanna
MGMarco Giulini
Marco Giulini
DADomenico Alberga
Domenico Alberga
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi
Dritan SiliqiDritan Siliqi
Dritan Siliqi
Shwachman–Diamond syndrome (SDS) is a rare autosomal recessive disorder characterized by pleiotropic phenotypes, including pancreatic insufficiency, skeletal abnormalities, and bone marrow dysfunction. Notably, patients with SDS exhibit an increased risk of developing myelodysplastic syndrome and leukemia. In this study, we employed a combination of comparative molecular dynamics (MD) simulations and small-angle X-ray scattering (SAXS)-based analysis to investigate the Shwachman–Bodian–Diamond syndrome protein (SBDS). Specifically, we explored the molecular basis of the syndrome by examining the conformational dynamics of a set of missense mutants of SBDS in comparison to those of the wild-type (WT) protein. Our observations suggest that different mutations may impact (i) the interaction of SBDS with the ribosome, (ii) the binding of SBDS to Elongation Factor-Like 1 (EFL1), and (iii) the SBDS rearrangements coupled to EFL1 binding. Extensive MD simulations, with a total simulation time of 17 μs, revealed variations in the interdomain flexibility of SBDS, which are consistent with previously published affinity data and the new SAXS experimental data presented here. We propose a structural rationale behind the previously reported weak interaction of mutants I167T, R175W, and I212T with EFL1. Additionally, SAXS data indicate that R19Q, I167T, and R175W mutants exhibit altered relative abundances of SBDS conformational states in solution, further supporting our computational results. Overall, our integrated computational and experimental approach provides a comprehensive understanding of how specific mutations in SBDS alter its structural dynamics and binding interactions. These insights enhance our broader understanding of SBDS function and its role in ribosome biogenesis.